对比增强锥形束乳腺CT:鉴别乳腺病灶良恶性最佳采集时间的分析
研究纳入31例患者57个BI-RADS 4或5类乳腺病灶,在注射对比剂后2分钟和3分钟行对比增强锥形束乳腺CT,恶性病灶在2分钟和3分钟强化均高于良性病灶,2分钟时良恶性强化差异最大,且导管原位癌强化最高。
要点
- 注射对比剂后2分钟采集的对比增强锥形束乳腺CT对乳腺病灶良恶性的鉴别效果最佳。
- 恶性病灶在2分钟和3分钟强化均高于良性病灶,2分钟时差异最大。
- 导管原位癌在恶性病灶中平均强化最高,3分钟达100.93 HU。
核心结论
- 对比增强锥形束乳腺CT在注射对比剂后2分钟采集时对乳腺病灶良恶性的鉴别效果最佳,强化程度有潜力区分组织病理学亚型,恶性病灶中导管原位癌强化最高。
研究设计与样本
- 研究纳入乳腺X线和/或超声发现BI-RADS 4或5类病灶的患者,所有患者均行平扫和注射对比剂后2分钟、3分钟的对比增强锥形束乳腺CT检查。
关键影像表现/征象
- 恶性乳腺病灶在2分钟对比增强锥形束乳腺CT的强化为48.17 HU,良性病灶为0.3 HU,p<0.001。
- 恶性乳腺病灶在3分钟对比增强锥形束乳腺CT的强化为57.38 HU,良性病灶为15.43 HU,p<0.001。
- 恶性与良性乳腺病灶的强化差异在2分钟对比增强锥形束乳腺CT时最大。
- 导管原位癌在3分钟对比增强锥形束乳腺CT的平均强化为100.93 HU,p=0.0314。
- 伴导管原位癌成分的浸润性癌非特殊型在3分钟强化为55.82 HU,浸润性导管癌为52.31 HU。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To investigate the optimal acquisition time of contrast-enhanced cone-beam breast-CT (CBBCT) for best discrimination of breast lesion malignancy and whether contrast enhancement can aid in classification of tumor histology.
MATERIAL AND METHODS: The study included patients with BI-RADS 4 or 5 lesions identified on mammography and/or ultrasound. All patients were examined by non-contrast (NC-CBBCT) and contrast-enhanced CBBCT (CE-CBBCT) at 2 and 3min after contrast media (CM) injection. Lesion enhancement of suspicious breast lesions was evaluated in corresponding CBBCT slices.
RESULTS: A total of 31 patients with 57 breast lesions, 30 malignant and 27 benign, were included. Malignant breast lesions demonstrated higher contrast enhancement than benign breast lesions at both 2min and 3min CE-CBBCT (2min: 48.17 vs. 0.3 HU, p<0.001; 3min: 57.38 vs. 15.43 HU, p<0.001). Enhancement differences between malignant and benign breast lesions were largest at 2min CE-CBBCT. Ductal carcinoma in situ (DCIS) showed highest mean contrast enhancement among malignant breast lesions (100.93 HU at 3min CE-CBBCT, p=0.0314) compared to invasive carcinoma of no special type with DCIS component (55.82 HU at 3min CE-CBBCT) and invasive ductal carcinoma (52.31 HU at 3min CE-CBBCT).
CONCLUSIONS: The contrast enhancement on CE-CBBCT best discriminates between malignant and benign breast lesions at 2min after CM injection. The enhancement has the potential to differentiate histopathological subtypes, with highest enhancement among malignant lesions seen for DCIS.
引用
- Uhlig J, Fischer U, Surov A, et al. Contrast-enhanced cone-beam breast-CT: Analysis of optimal acquisition time for discrimination of breast lesion malignancy. Eur J Radiol. 2017. PMID: 29362157. doi:10.1016/j.ejrad.2017.12.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。